Alma launches Veil in Canada

Alma North America has launched Alma Veil in Canada, giving medical aesthetic practices a single handpiece that combines 532 nm, 1064 nm and MicroPulse™ technologies. The company says the platform is designed to help providers tailor treatment for vascular, pigmented and skin quality concerns with minimal downtime and no required treatment consumables.

Why it matters: - Alma Veil gives Canadian medical aesthetic practices one platform for multiple treatment targets, including superficial and deeper vascular concerns and skin quality. - The system is designed to reduce equipment complexity by combining three technologies in one handpiece. - The launch adds another configurable option for dermatologists, plastic surgeons, physicians and other medical aesthetic professionals.

What happened: - Alma North America announced the Canadian launch of Alma Veil, a multi-technology platform for medical aesthetic professionals across Canada. - Alma Veil officially launched in Canada on August 24, 2026. - The platform is now available to practices seeking individualized treatment approaches for vascular, pigmented and skin quality concerns.

The details: - Alma Veil combines 532 nm and 1064 nm wavelengths with MicroPulse™ technology. - The 532 nm wavelength is designed for superficial vascular lesions. - The 1064 nm wavelength is designed for deeper vascular lesions. - MicroPulse technology is intended for skin quality treatments with minimal downtime. - The platform uses a single handpiece that integrates all three technologies. - Contact cooling is included for patient comfort and safety. - The workstation does not require cryogens, dyes or other treatment consumables. - The system is built for platform stability and consistent energy delivery. - DermaCore™ Delivery is engineered to modulate pulse sequence and support simultaneous targeting of larger and smaller vascular structures in each pulse. - Cory Murrell, general manager for Canada, said the platform gives practices a versatile way to address a broad range of patient needs. - The company says providers can use the technology best matched to the clinical concern and treatment plan.

Between the lines: - The launch reflects Alma North America’s push to position a single device as a flexible workflow tool rather than a single-indication system. - The no-consumables setup may lower operational friction for practices that want fewer recurring treatment inputs. - A cited multicenter retrospective case series gives Alma Veil early clinical support in routine practice, but the evidence base is still limited. - In that study, 13 adults were treated across three dermatology practices for vascular-predominant rosacea and facial telangiectasia. - Treating physicians reported a mean Global Aesthetic Improvement Scale score of 4.23 out of 5. - Mean patient satisfaction was 4.31 out of 5. - Independent blinded reviewers found moderate-to-high photographic improvement. - Mean reported pain was 2.54 out of 10, and no adverse events were reported. - The authors concluded that a depth-directed 532/1064 nm workflow produced clinically meaningful clearance with high patient satisfaction and low discomfort in routine practice.

What's next: - Alma North America says providers interested in learning more can visit the company's website or contact a local Alma representative. - The launch expands Alma North America’s portfolio in Canada as the company continues to market energy-based technologies for aesthetic and surgical use.

The bottom line: - Alma Veil enters Canada as an all-in-one platform aimed at giving aesthetic practices more treatment flexibility with fewer consumables and multiple wavelength options.